The facility was acquired from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc.

WuXi XDC Cayman Inc. ('WuXi XDC', or the 'Company', stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug ...

In a recent study published in the Journal of Experimental Medicine, a multi-institutional research team led by Osaka ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

Does a claim that merely recites an inherent property of an otherwise obvious claim require an additional analysis to demonstrate that a person ...

Wexford-based biopharmaceutical company Coeptis Inc. announced the formation of GEAR Therapeutics, a majority-owned ...

MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Pierre Fabre SA and Redridge Bio AG have signed an exclusive R&D collaboration and license agreement to identify and develop ...

Inatherys SAS recently presented preclinical data for INA-03, an anti-transferrin receptor (TfR1/CD71) antibody-drug conjugate (ADC), being developed for the treatment of triple-negative breast cancer ...

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

Vaccine effectiveness relies on creating a strong antibody response that can be reactivated to fight future infections. Now, ...